The Egyptian Drug Authority (EDA) has updated the Regulatory Guidelines for Adding or Transferring Manufacturing Locations of locally registered Human/Veterinary pharmaceuticals to enhance regulatory compliance, traceability, and quality assurance. The 2025 update provides clear procedures for requesting site additions or transfers, emphasizing timely approvals and adherence to technical and stability requirements.
- Scope & Authority: Responsibilities clarified between the Central Administration for Inspection of Pharmaceutical Establishments and Variables Management.
- Change Classification: Manufacturing changes classified as Major or Minor based on technique similarity, aligned with WHO TRS 961.
- Stability Requirements: Accelerated (6 months) and long-term studies required; additional pre-release checks for Major changes.
- Submission & Timelines: Referral letters valid for 3 months; technical reports submitted within 1 month.
- Analysis & Inspection: Decisions on analysis location depend on latest inspection reports within a two-path framework.
- Advisory Notes: Guidance is non-binding; companies may reapply if necessary.
This update reinforces the EDA’s commitment to supporting local pharmaceutical manufacturing while ensuring the availability of safe, high-quality, and effective products.
Select Mandate HA
Select Mandate Function